Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

somapacitan

Gilead Sciences

Gilead’s ulcerative colitis antibody flunks trial

Halts trial early as preliminary data shows no evidence of efficacy

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

- PMLiVE

GSK throws gauntlet down to Merck with shingles vaccine data

Shingrix trial reported ninety per cent efficacy in elderly patients who do not respond well to Zostavax

Deal Watch August 2016

Pfizer's hat trick as well as Sanofi, GlaxoSmithKline, Boehringer Ingelheim and more are featured in this month's round-up

- PMLiVE

Pfizer launches app to help patients manage depression

Hopes the Moodivator app will complement treatment and support care teams

Sanofi reception

Sanofi trumpets new IGlarLixi data after regulatory delay

Reports that the combination drug is more effective at controlling glucose than Lantus alone

- PMLiVE

A new era of collaboration

Looking at the factors driving this change and assessing the benefits

- PMLiVE

Pfizer appoints chief scientific officer

Dr Ole Isacson will lead the neuroscience research unit

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links